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Liver is one of the most important organs needing great concern during the 
perioperative period. There are a number of different mechanisms that interact 
with liver cells and might affect their integrity and cell live. Though these 
mechanisms are not all the same, there is a great common point: all affect the 
metabolic pathways of the liver. Ischemia, anesthetic drug effects and other 
perioperative insults may affect the liver. Disturbance in an organ’s blood 
flow is an inherent part of diverse surgical procedures, which leads to lack of 
oxygen and nutrient supply. These ischemic periods can be particularly long 
in case of liver surgeries, such as resection of large hepatic tumors, 
management of hepatic trauma and liver transplant. Once the blood flow and 
oxygen supply are restored, the interruption of blood flow affects the oxygen 
dependent cells in liver, which require mitochondrial oxidative 
phosphorylation for their metabolism. Molecular mechanisms such as Redox 
status, ionic interchange disturbances as well as different mediators and cells 
like KC, SEC, dendritic cells, leukocytes, and lymphocytes, are involved in 
the process ultimately leading to cell death by apoptosis and necrosis.  This 
review provides an overview on the cellular and molecular mechanisms 
involved in liver injuries, categorizing these mechanisms in 3 different 
classes: preoperative mechanisms, intraoperative mechanisms and 
postoperative mechanisms. Each of them are discussed in a different part of 
the manuscript. 
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Introduction 
Disturbance in an organ’s blood flow is an 
inherent part of diverse surgical procedures, which 
leads to lack of oxygen and nutrient supply. These 
ischemic periods can be particularly long in case of 
liver surgeries, such as resection of large hepatic 
tumors, management of hepatic trauma and liver 
transplant (1). Once the blood flow and oxygen 
supply are restored, the interruption of blood flow 
affects the oxygen dependent cells in liver, which 
require mitochondrial oxidative phosphorylation for 
their metabolism. Molecular mechanisms such as 
redox status, ionic interchange disturbances as well as 
different mediators and cells like KC, SEC, dendritic 
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cells, leukocytes, and lymphocytes, are involved in 
the process ultimately leading to cell death by 
apoptosis and necrosis (2). 
There are 2 major types of ischemic 
reperfusion liver injury: Warm IR injury occurs 
during prolonged surgical liver resection using 
clamping of the perfusion and is nearly inevitable in 
liver resection surgery, liver transplantation, and in 
blood transfusion for hemorrhagic shock (3). Cold IR 
injury, on the other hand, results from cold 
preservation of the donor organ followed by 
restoration of blood flow after implantation during 
liver transplantation (2). Tissue damage during an 
ischemic reperfusion injury occurs in two phases: The 
early phase which occurs within the first 2-6 hours 
after the blood supply has been re-established is 
presumably the consequence of the fast change in the 
redox state of the liver tissue. It is characterized by 
the release of reactive oxygen species (ROS) and 
production of inflammatory mediators (TNFα, 
chemokines) by hepatocytes, Kupffer cells (KCs), and 
sinusoidal endothelial cells (SECs). The late phase 
which occurs 6–48 h after reperfusion further 
advances the liver damage and is caused by the 
production of inflammatory cytokines and 
chemokines as a result of the infiltration of 
neutrophils and macrophages into the liver tissue (1–
3). 
Clinically, liver IR injury can lead to elevation 
in liver enzymes and biliary dysfunctions which can 
even lead to liver failure (4). Furthermore, many other 
remote organs seem to be influenced during the 
process of IR liver injury, including kidney, lung, gut, 
pancreas, adrenal and Myocardial injury (5), which 
further increases the mortality after perioperative liver 
failure (6). This articles aims to review the main 
strategies implemented to minimize perioperative 
hepatic cellular injury. 
Pre-operative Considerations  
Since the extent of perioperative liver IR injury 
mainly depends on the duration of ischemia and 
preexisting health conditions, a targeted perioperative 
liver protection is only possible by obtaining the 
detailed knowledge and thorough assessment of 
preoperative liver impairment (7). Liver has the 
ability to compensate for temporary insults and 
regenerate itself to a certain degree as a result of its 
dual blood supply from portal venous and hepatic 
 
Figure 1. Proposed algorithm for the preoperative assessment of patients with liver disease (adapted from reference 12). 
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arterial blood flow (7), hence the liver injury occur 
only be clinically evident after substantial damage. 
However, this reserve capacity is significantly 
reduced in patients with advanced liver disease, and 
these patients are more prone to develop an 
inappropriate response to surgical stress, 
coagulopathy and hepatic encephalopathy. Evaluation 
of general health and co-morbidities such as 
coagulopathy, renal function, volume and electrolyte 
status and cardiovascular function, is therefore 
essential in order to anticipate the patient’s individual 
needs during and after the surgery (8). 
Cardiovascular assessment 
In patients with liver cirrhosis, the systemic 
circulation is hyperdynamic and significantly 
dysfunctional and impaired myocardial contractility 
lead to limited contractile reserve to meet 
perioperative hemodynamic challenges. Additionally, 
the response to potent vasoconstrictors, such as 
angiotensin II and vasopressin and epinephrine 
injection, is blunted due to down regulation of 
receptors. Thus, it is difficult to maintain adequate 
intraoperative end organ perfusion in these patients. 
Pre-operative echocardiography and either an exercise 
or pharmacological stress-test is needed to ensure 
patients safety during the surgery (8).  
Pulmonary assessment 
The hepatopulmonary syndrome (HPS) and 
portopulmonary hypertension (POPH) and hepatic 
hydrothoraxare known to occur in chronic liver 
disease and should be evaluated before surgery to 
minimize the risk of hypoxia and right heart failure 
(9). The clinical features of HPS are present in about 
15% of patients with chronic hepatic disease and may 
have adverse effects on maintaining the adequate 
perioperative liver perfusion and oxygenation (8). 
POPH, is about 10 times less common than 
HPS and it is diagnosed based on pulmonary 
hemodynamic criteria acquired through right heart 
catheterization (8). Moderate and severe POPH can 
Table 1: Overview of preoperative management of liver disease complications (Adapted from reference 12). 
 
Clinical manifestation Management considerations  
Nutritional status Maintenance of an adequate protein intake (1–1.5 g/kg 
per day) 
Consider DR  
Coagulopathy Vitamin K supplementation (oral or parenteral) 
Fresh, frozen plasma transfusions  
Intravenous administration of cryoprecipitate 
Intravenous administration of recombinant factor VIIa 
Platelet transfusions 
Ascites Paracentesis with analysis of ascitic fluid for evidence 
of infection 
Dietary sodium restriction (<2 g daily) 
Oral diuretic therapy with spironolactone and/or 
furosemide 
Fluid restriction (if sodium concentration is <120 
mmol/l) 
Avoidance of excessive saline administration 
Avoidance of NSAIDs 
Renal dysfunction Avoidance of nephrotoxic insult 
Albumin infusion (with paracentesis volumes >5 l) 
Portosystemic encephalopathy Correction of reversible metabolic factors  
Avoidance of sedatives and opioid narcotics, as far as 
possible 
Oral lactulose administration, titrated to ~3–4 bowel 
movements per day 
Administration of nonabsorbable antibiotics  
Decreased protein intake 
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substantially increase the risk associated with liver 
transplant (10). Screening for POPH is advised using 
transthoracic Doppler echocardiography and right 
heart catheterization (8). 
Preoperative blood gas analyses can also help 
in understanding the underlying mechanism of 
hypoxia, since patients with intra-pulmonary shunting 
are likely to have no or very little response in PaO2 
after 100% inspiration of Oxygen, whereas patients 
with ventilation– perfusion mismatching or dilated 
alveolar capillaries are more likely to have a normal 
response (PaO2>500 mmHg) (8). 
Renal assessment  
Patients with chronic liver disease are at risk 
for renal dysfunction with renal hypoperfusion due to 
hemodynamic abnormalities. The risk of developing 
dysfunction is increased by diuretics, nephrotoxic 
agents including non-steroidal anti-inflammatory 
drugs (NSAIDs), large-volume paracentesis 
performed without albumin supplementation, 
infections, and gastrointestinal bleeding. Another 
common condition in this patient population is 
Hepatorenal syndrome, which is caused by alterations 
in renal blood flow following splanchnic 
vasodilatation (9). 
Renal function should be closely monitored 
before and after the surgery, and potential insults 
should be dealt with accordingly. It should be noted 
that due to hemodynamic changes serum creatinine 
levels often overestimate the glomerular filtration rate 
(GFR) in patients with cirrhosis. Vasoactive 
compounds, midodrine and terlipressin as well as 
intravenous albumin are used in treatment of 
circulatory problems and the resultant renal 
impairment in patients with cirrhosis and reduced 
interstitial volume (9). 
Renal dysfunction can lead to hyponatremia 
which in severe cases (<125 mEq/l) must be 
addressed carefully to avoid central pontine 
myelinolysis (11). 
Coagulation profile assessment 
 All coagulation factors, except von 
Willebrand’s factor are produced in the liver. The 
impaired production of coagulation factors, along 
with alterations in vitamin K metabolism and 
absorption due to cholestasis, enhanced fibrinolytic 
activity and/or peripheral thrombocytopenia due to 
entrapment of platelets as a result of portal 
hypertension, leads to coagulopathy in advanced liver 
diseases (8,9). The coagulation profile should be 
assessed and corrected, depending on the surgical 
procedure with vitamin K supplementation and 
administration of fresh-frozen plasma (FFP), 
Cryoprecipitate to reduce the prothrombin 
time,diamino-8-D-arginine vasopressin (DDAVP) for 
prolonged bleeding time and platelet transfusion to 
correct the thrombocytopenia (8,9). Blood 
temperature should be maintained using warmed 
fluids or warm-air devices to ensure adequate 
function of coagulation cascade during surgery. 
Platelet function might be impaired despite a normal 
platelet count, which can affect neuraxial anesthesia 
(8). 
Other factors 
Other conditions that should be addressed 
before the surgery are as follows: 




1 point 2 points 3 points 
Total bilirubin concentration 
(μmol/l)c 
<34 34–50 >50 
Serum albumin concentration (g/l)
* 
>35 28–35 <28 
International normalized ratio <1.7 1.7–2.2 >2.2 
Ascites None Controlled with 
medication 
Treatment-refractory 




* For patients with chronic cholestatic diseases, assign 1 point for a bilirubin concentration of up to 68 μmol/l, 2 
points for a bilirubin concentration of 68–170 μmol/l, and 3 points for a bilirubin concentration >170μmol/l 
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Ascites: ascites should be treated aggressively 
with diuretics and/or large-volume paracentesis with 
regards to renal function before surgery, as it can lead 
to wound dehiscence, abdominal wall herniation, and 
respiratory problems due to reduced lung expansion, 
and increase mortality (9). 
Encephalopathy: Portosystemic 
encephalopathy at baseline can increases risk of 
postoperative encephalopathy and mortality rate in 
cirrhosis patients. Addressing the underlying cause of 
encephalopathy, whether it is electrolyte 
abnormalities, infection, gastrointestinal bleeding, or 
sedatives may help prevent or decrease 
encephalopathy. Hepatic encephalopathy can also be 
treated with administering lactulose or poorly 
absorbed antibiotics such as rifaximin (9). 
Malnutrition: Severe malnutrition increases the 
need for emergency supplies of packed red blood 
cells, FFP, and cryoprecipitate and is believed to 
prolong postoperative stay. Therefore it should be 
addressed in the preoperative period with supplements 
accordingly, to meet increased energy expenditure 
after surgery and improve surgery outcomes (9). 
Preoperative nutritional interventions (mainly 
fasting and dietary restrictions for periods longer than 
the night before surgery) have been suggested as a 
way to protect against certain types of stress, such as 
ischemia-reperfusion injury. Although sufficient data 
are available to support this theory, there is a need for 
more detailed studies to determine the best nutritional 
intervention for each patient, as protein restriction can 
have the same results without calorie restriction, and 
can be combined with carbohydrate rich drinks in 
patients to protect the organ without compromising 
patient’s health. Some pharmacological interventions 
can mimic these effects, for example resveratrol, a 
natural polyphenol, can induce genomic changes 
similar to ones induced by DR. resveratrol can also 
alleviate liver injury induced by ischemia-reperfusion 
injury, through a meaningful increase in glutathione 
reductase, copper-zinc superoxide dismutase, and 
catalase activities (12). Table 1 demonstrates an 
overview of the preoperative considerations (Table 1). 
Quantified risk assessment 
In order to quantify the risk associated with 
surgery in patients with chronic liver disease, two risk 
stratification schemes have been introduced: The 
Child–Turcotte–Pugh (CTP) score in 1984 and, the 
model of end-stage liver disease (MELD) in 1999. 
The CTP score was originally designed by Child and 
Turcotte and Pugh et al. modified it by including 
prothrombin time in place of nutritional status for use 
in patients undergoing esophageal transactions. The 
score was originally used to assess risks in patients 
undergoing portosystemic shunting for variceal 
hemorrhage, but subsequent studies have shown its 
benefits to determine risks of surgery in patients with 
liver disease. This score is widely used to assess 
disease severity and predict perioperative morbidity 
and mortality in patients with cirrhosis. The score is 
calculated with components in Table 2, with class 
A=5–6 points, class B=7–9 points, and class C=10–15 
points. CTP classes A, B, and C are associated with 
mortality of 10%, 30–31%, and 76–82%, respectively 
in patients with liver disease (8,9,13) (Table 2).  
The clinical parameters used in CTP scoring 
system are subjective and the cut-off points for 
biochemical parameters are inconsistent, therefore 
alternative systems have been developed in order to 
increase the accuracy in estimating the severity of 
underlying hepatic dysfunction. The model of end-
stage liver disease (MELD) was designed for this 
purpose in 1999. This score is calculated from the 
patient’s serum creatinine (Crea), bilirubin (Bil), and 
international normalized ratio (INR) instead of 
subjective clinical parameters (8,13).  
MELD score = (9.6 × ln [creatinine mg/dl]) + 
(3.8 × ln[bilirubin mg/dl]) + (11.2 × ln [INR]) + 6.4. 
The MELD score has been used in patients with 
cirrhosis, variceal bleeding or acute alcoholic 
hepatitis (14–16). A modified version of this model is 
adopted by the United Network for Organ Sharing (as 
of February 2002) to select patients for liver 
transplantation (15) (Figure 1) 
Anesthetic Considerations  
Volatile agents  
It seems that all volatile anesthetics have the 
potential to harm the liver. The mechanism for this 
adverse effect is mainly immunologic; 
biotransformation of these agents by cytochrome 
P450 Specific results in trifluroacetylated proteins 
which can trigger an immune response in genetically 
susceptible individuals in the form of specific IgG 
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antibodies. The reaction of these antibodies with cell 
surface antigens of hepatocytes, increases incidence 
of antibody-dependent cell-mediated toxicity in these 
cells (17, 18). Halothane and enflurane are the main 
inhaled anesthetics that are most frequently associated 
with postoperative liver damage with this mechanism. 
The incidence of enflurane-induced hepatotoxicity 
appears to be less than halothane (19). Since 15–40% 
of Halothane and about 2.5 % of enflurane are 
metabolized in liver by cytochrome P450, it can be 
assumed that there is a cross-sensitization between 
enflurane and halothane and enflurane may not be the 
causative agent in the reported hepatotoxicity (20) .  
There have been reports of different grades of 
hepatotoxicity with isoflurane which supposedly 
involves a similar mechanism, although the 
biotransformation of this agent is minimal (0.2%). On 
the other hand, isoflurane and sevoflurane can have a 
hepato-protective effect too (21). These agents induce 
an upregulation of hemoxygenase-1 (HO-1), which 
catalyzes the conversion of hem to biliverdin IX, free 
iron and carbon monoxide and ultimately leads to 
vasodilation of hepatic vascular bed (7). 
Desflurane is metabolized by cytochrome p450 
system to a small but variable extent (about 0.02%) 
which can potentially form immunogenic complexes, 
with several cases reported in the literature (22–24). 
However, preserves a better hepatic blood flow 
compared to earlier generations of volatile anesthetics 
such as halothane and enflurane. It is also associated 
with better outcomes in maintenance of anesthesia for 
liver transplantation comparison with total IV 
anesthesia (25).  
Sevoflurane is the newest form of halogenated 
anesthetics. Its biotransformation is minimal and does 
not lead to the formation of reactive trifluroacetylated 
proteins; therefore it is unlikely to cause severe 
postoperative hepatic injury and can be considered as 
a perfect anesthetic for patients with previous 
exposure to other halogenated anesthetics or hepatic 
disease. Pretreatment with Sevoflurane can be used as 
a hepatoprotective strategy due to its vasodilation 
effect on hepatic vascular bed (19) 
In Recent years, Xenon has gained much 
attention as an anesthetic gas with nearly all the ideal 
features. Xenon anesthesia has been shown to produce 
“the highest regional blood flow in the brain, liver, 
kidney and intestine” which is the goal in patients 
undergoing liver surgeries (26) 
Intraoperative Considerations  
Surgical measures  
Portal triad clamping was the earliest method 
reported to reduce blood loss during liver resection. 
The maneuver is easily applicable in different 
situations (except for lesions in the hepatic veins or 
inferior vena cava and in patients with right heart 
failure and pulmonary hypertension), is considered 
effective and it is well tolerated in the majority of 
patients, however some complications including 
significant increase in mean arterial pressure and 
systemic vascular resistance, reduction of cardiac 
index, splanchnic congestion and bacterial 
translocation from the gut has been associated with 
PTC in the literature. Intermittent application of PTC 
and ischemic preconditioning was later introduced to 
improve outcomes in liver surgeries. Intermittent PTC 
may increase the total blood loss compared to 
continuous PTC, but it can reduce the incidence of 
postoperative liver failure, particularly in the presence 
of cirrhosis. In ischemic preconditioning, an increased 
tolerance to prolonged ischemia is induced in the liver 
by exposure to short periods of liver ischemia prior to 
transection with PTC, either surgically or by 
administration of chemical compounds. A meta-
analysis on this technique has not shown any 
significant difference in mortality, blood loss or liver 
failure, although length of intensive care unit and 
hospital stay have been improved significantly 
(27,28). The liver can tolerate some episodes of warm 
ischemia, but especially in case of patients with 
preexisting liver damage due to chemotherapy or 
cirrhosis, it is vulnerable to anoxic conditions. 
Although several studies demonstrated ≤90 mininutes 
of complete PTC to be safe in normal livers, many 
surgeons choose to not clamp the inflow continuously 
for >45 minutes to prevent concern occult liver 
damage. In cases of complex liver surgeries with 
prolonged clamping time, ischemic preconditioning 
may be preferred (29). 
Stricter vascular isolation of the liver provides 
better control of hemorrhage, but it also increases the 
ischemic injury in the organ, congestion of the viscera 
and cardiac stress. Total inflow and outflow occlusion 
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of the liver is used in “Total hepatic vascular 
exclusion”. This technique which can be combined 
with aortic clamping and hypothermic perfusion of 
the liver is intolerable for some patients due to an 
unexpected fall in cardiac output and is therefore 
commonly reserved for resections involving the 
inferior vena cava or hepatic veins. In Hemihepatic 
vascular clamping (HHVC), the vascular isolation is 
reduced and therefore ischemia to the liver remnant 
and splanchnic congestion is minimized but the risk 




As mentioned before, patients with chronic 
liver disease require a more restrict control of arterial 
blood pressure, since they are at a greater risk of 
ischemic and reperfusion injury due to their is 
impaired functional reserve capacity . 
A low central venous pressure (CVP) between 
2 and 5 mmHg should be maintained in order to 
reduce intraoperative blood loss due to hepatic vein 
distention. Fluid replacement should be considered 
afterwards to compensate the reduced organ perfusion 
and volume reserve. 
Several vasoconstrictive agents have been used 
to maintain macrohemodynamic variables and tissue 
oxygenation. These agents increase oxygen 
consumption in the organ as well which may have 
adverse effects on overall nutritional blood supply (8). 
Epinephrine and norepinephrine, dopamine, 
dobutamine and dopexamine all improve mean 
arterial pressure and cardiac output. In patients with 
sepsis, however, epinephrine had the potential to 
impair splanchnic circulation with its effect differing 
with the degree of underlying sepsis. In these patients, 
dopexamine could not increase splanchnic blood flow 
selectively, and did not improve surgery outcomes 
and organ dysfunction in major abdominal surgery. 
The reports on dopamine are controversial, and it has 
been suggested that its effects on splanchnic blood 
flow may be dependent on basal splanchnic perfusion 
(8). A cross-over study compared epinephrine with a 
combination of dobutamine and norepinephrine in 
septic shock patients. Results demonstrated 
improvement in splanchnic blood flow and oxygen 
uptake in the group using the combination of 
dobutamine and norepinephrine (30). There are 
several reports of dobutamine hepatoprotective effects 
with mechanisms similar to isoflurane (31). In a 
sepsis model in rats, dobutamine pretreatment 
Improved Survival, Liver Function, and Hepatic 
Microcirculation (32). 
Vasopressin has shown to restore blood 
pressure rapidly in septic shock but its effects on 
splanchnic and hepatic blood flow are controversial 
(8). In a recent study on human subjects in hepatic 
surgery, vasopressin increased cardiac output, stroke 
volume, MAP and CVP. Systemic vascular resistance, 
heart rate and portal venous pressure remained 
unchanged, and HVP increased slightly. Vasopressin 
infusion also reduced portal and hepato-splanchnic 
blood flow (33). Dexmedetomidine, a selective α 2 
adrenoceptor agonist, has the unique ability to induce 
sedation and analgesia at the same time, without 
increasing the risk of respiratory depression. DEX can 
reduce sympathetic drive, which makes it a more 
appropriate choice for analgesia in patients who are at 
risk of tachycardia and hypertension. According to 
pre-clinical data, DEX also has profound organo-
protective effects in cerebral, cardiac, renal, hepatic 
and gastrointestinal ischemia-reperfusion injury but 
further clinical trials are needed to warrant its use in 
practice (34). 
Phosphodiesterase inhibitors showed promising 
results in septic patients where an increase in 
hepatosplanchnic oxygen consumption, lidocaine 
metabolism and a decreased release of hepatic tumor 
necrosis factor alpha (TNF-α), was seen with 
enoximone treatment (8). Preoperative olprinone also 
showed improvement in systemic and hepatic 
circulation in a swine partial hepatectomy model (35). 
Pentoxyphilline, which is used in intermittent 
claudication, is also a phosphodiesterase inhibitor. 
Furthermore, it inhibits inflammatory cytokines such 
as TNF-αand protects the liver against ischemia and 
reperfusion injury (36). 
Levosimendan, has also been shown to 
hepatoprotective effects on hepatocytes (37). A study 
compared the effects of levosimendan and 
dobutamine on hepatic blood flow of the patients with 
low cardiac output in cardiac surgery, and the results 
suggested that levosimendan can improve hepatic 
blood flow as a selective liver vasodilator through the 
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hepatic artery and also the portal vain, while 
dobutamine has no vasodilating effect on the hepatic 
artery and only enhances the portal venous blood flow 
(38). Levosimendan can exert protection against 
ischemic liver damage through mechanisms related to 
NO production and mitochondrial KATP channel 
function (39) and significantly improve liver redox 
homeostasis (40) 
Pharmacologic Interventions  
Pharmacological preconditioning  
As mentioned before, Pharmacological agents 
such as inhaled anesthetics can be used in 
preconditioning. PP induces a stress response which 
protects liver against IR injury. 
Some of the agents used for PP are as follows: 
Nitric oxide: NO has demonstrated a decrease 
in IR liver injury by reducing apoptosis in hepatic 
cells, alleviating oxidative stress and leukocyte 
adhesion, and also increasing the capillary blood 
flow, and improving mitochondrial function (41). 
Doxorubicin: Doxorubicin preconditioning can 
induce ischemic tolerance and IR injury protection in 
rats abdomen island (42) , But its associated liver 
toxicity limits its clinical use. 
Volatile anesthetic agents: Isoflurane and 
sevoflurane have been found helpful in prevention of 
IR liver injury, through previously discussed 
mechanisms. 
Propofol: Propofol have some advantages in 
prevention of IR liver injury, by reducing lipid 
peroxidation, the number of apoptotic cells and 
activation of Caspase-3 in hepatic L02 cells, but the 
results are somewhat controversial (43,44). 
Verapamil has hepatoprotective effects in 
warm liver ischemia when administered before an 
ischemic insult in rat models, but no protective effect 
was seen with administration after induction of 
ischemia or during the early reperfusion period (44). 
Lignocaine: Injection of Lignocaine into 
hepatoduodenal ligament improves hepatic blood 
circulation, decreases neutrophil infiltration and 
ultimately reduces hepatic necrosis blocking hepatic 
nerves. Its membrane‑stabilizing effects, further 
inhibits the neutrophil function. Liver perfusion with 
lignocaine has been seen to increase the survival and 
reduce liver enzymes after liver surgeries (29). 
Adenosine: Adenosine prevents down 
regulation of eNOS during IR liver injury and 
therefore has hepatoprotective effects (29).  
Ozone: Xantine and adenosine are accumulated 
in the cell as a result of adenosine triphosphate (ATP) 
degradation after IR liver injury. Ozone therapy 
blocks xanthine and xanthine oxidase pathways, thus 
inhibits ROS formation and its associated hepatic 
injury during hepatic IR process (29). Ozone 
treatment and surgical preconditioning have similar 
biochemical effects but ozone seems to be more 
beneficial in the histological aspects (45).  
Remifentanil: Preconditioning with 
remifentanil reduces liver injury in IR both in vivo 
and in vitro through Inducible NOS which exhausts 
reactive oxygen species and therefore diminishes the 
inflammatory response (46). 
Glucocorticoids: Over the last decade, 
randomized controlled trials (RCTs) has shown that 
preoperative administration of glucocorticoids in 
patients undergoing liver resection can have 
beneficial effects on biomarkers of systemic 
inflammation, including IL-6, IL-10, TNF-α, C 
reactive protein (CRP), liver function tests such as 
AST, ALT, prothrombin time (PT) and total bilirubin, 
with no increased risk for infection or negative effects 
on liver regeneration (47). 
Trimetazidine: trimetazidine is an anti-angina 
medication with both cytoprotective and antioxidant 
abilities which can preserve energy metabolism in 
cells exposed to hypoxia or ischemia. It has been 
shown to reduce cytolysis and increase liver ATP 
content with vascular clamping during hepatic IR 
injury and reduce hospital stay in human subjects 
(48). 
Glucose: Administrating high concentrations 
of glucose 24 h prior to surgery has shown an increase 
in hepatic ATP content due to higher hepatic 
glycogen storage (29). 
Iron and Thyroid hormone: A combination 
ofiron and T3 was used in a study to suppressed 
ischemia–reperfusion injury in rat livers. The 
combination was able to attenuate the oxidative stress, 
Nrf2 and NF-kB activation, and upregulations in 
glutamate-cysteine ligase-c and haptoglobin (49). 
Antioxidants and other pharmacological 
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agents: as oxidative stress and inflammatory 
pathways play a major role in IR liver injury, different 
antioxidants and anti-inflammatory agents including 
vitamins C and E, N-acetyl cysteine (50), statins (51), 
S-adenosyl methionine (48), melatonin (52) and 
several herbal extracts such as Silymarin in Milk 
thistle (53,54), grape skin component resveratrol and 
green tea extracts (55), cannabinoids (56) and 
Ginsenoside Rg1, the major effective component of 
ginseng (57), has been suggested to attenuate 
ischemic reperfusion liver injury. However it is 
usually difficult to predict their efficacy in the clinical 
use due to lack of information about their exact 
mechanism of action. 
Novel Strategies 
Different approaches are being pursued in 
experimental models to minimize preoperative 
hepatic injury, with promising results but limited 
clinical data. Some of these are as follows: 
Antioxidants targeting mitochondrial stress: 
Edaravone is an antioxidant drug specifically 
designed to reduce the effects of ischemia reperfusion 
by inhibiting MPT (Mitochondrial permeability 
transition) channel formation in mitochondria. It has 
shown to be highly effective in protecting against 
both warm and cold hepatic IR injury in rodents and 
larger mammals (55). 
Cytoprotective Strategies: A number of 
pharmacological interventions has been proposed in 
this category, including Calcium channel blockade 
(CCB) , low-dose therapeutic use of carbon monoxide 
(CO) as a cytoprotective, vasoactive and anti-
inflammatory drug, Emricasan as a pan-caspase 
inhibitor (caspase enzymes are involved in the cell 
apoptosis process) and Glycine as a cytoprotective 
agent working by reducing the oxidative stress of 
proteolysis (48). 
Preservation Solutions: Carolina rinse solution 
(CRS) and AQIX RS-I© has been introduced to 
prevent reperfusion injury in endothelial cells, but 
clinical data on their use is insufficient (48). 
Prostaglandins have been extensively 
evaluated for IR hepatic protection, with controversial 
results. A recent study on prostaglandin I2, found it 
clinically beneficial in reducing hepatic injury 
biomarkers in liver transplant surgery. Other 
immunologic drugs such as TNF-α inhibitors, 
Platelet-activating factor (PAF) antagonists, adaptive 
Immune System suppressors such as tacrolimus and 
everolimus (58) and Innate Immune System 
suppressors such as eculizumab (an anti-C5 antibody) 
and Gadolinium chloride (an inactivator of Kupffer 
cells) has also been suggested in experimental models 
(48).  
Gene therapy strategies: These strategies target 
redox sensitive pathways in mitochondria with an 
emphasis on intracellular nuclear factor kappa B 
(NFκB) and activator protein-1 (AP-1). The results 
from animal models were promising but there is a 
long way remaining to their use in clinical practice 
(29). 
Postoperative Care 
For Patients with underlying liver disease 
mortality rates are up to 10 fold higher in post-
operative period of liver surgeries (8). Signs of 
hepatic decompensation, including encephalopathy, 
coagulopathy, ascites, worsening jaundice and renal 
dysfunction, should be monitored in patients with 
underlying liver disease so that the treatment can be 
initiated immediately.  
Liver depletion of glycogen and decreased 
gluconeogenesis can lead to hypoglycemia in these 
patients; therefore serum glucose levels should be 
monitored.  
Intravascular volume should be maintained 
carefully to ensure adequate perfusion in kidney and 
liver, whilst minimizing the risk for hepatic 
congestion which can lead to edema, ascites, and 
wound dehiscence (59). Due to increased cardiac 
output and splanchnic blood flow which persists for at 
least 3 days after liver resection surgery, patients 
often experience mild-to-moderate pulmonary edema 
and transient ascites (60). Therefore close monitoring 
is advised for early detection of complications in all 
patients undergoing major liver resection and patients 
with significant preoperative liver damage 
Conclusion  
Surgical techniques and perioperative care has 
progressed significantly in recent years and liver 
surgery has become dramatically safer, with a 
mortality rate lower than 1% in patients with normal 
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preoperative liver function (61), however ischemic 
reperfusion injury of the liver still remains a problem. 
Appropriate protective strategies, surgical or 
pharmacological, should be considered in every step 
of the way, before, during and after the surgery, with 
regards to patients needs to minimize this injury and 
improve surgery outcomes. 
Although countless studies are published every 
year with focus on minimization of the IR liver injury 
with promising effects in vitro or on animal models, 
clinical data is still limited in this matter and 
conducting large randomized clinical trials can help 
facilitate the transition of these numerous preventive 
measures in to the clinical setting and fill in the gaps 
toward a more personalized treatment plan for each 
patient. 
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